ARTICLE | Clinical News
INCB7839: Development discontinued
November 7, 2011 8:00 AM UTC
Incyte disclosed in its 3Q11 earnings that it discontinued development of INCB7839 to treat metastatic breast cancer. Incyte said the decision was based on an analysis of tissue samples from >300 brea...